Aptorum ALS-4 Study Starts Dosing In Healthy Volunteers

by Vandana Singh, Benzinga Editor

March 31, 2021 9:54 AM | 1 min read |

Aptorum Group Ltd APM has dosed the first human subject in its Phase 1 trial evaluating ALS-4, an orally-administered small molecule drug to treat infections caused by Staphylococcus aureus, including MRSA.
The Phase 1 trial will evaluate the safety, tolerability, and pharmacokinetics of ALS-4 in healthy adult volunteers.
The study plans to enroll up to 48 and 24 volunteers for the single-ascending dose (SAD) and multiple-ascending dose (MAD) cohorts, respectively. Enrollment for the first cohort of SAD has been completed.
Price Action: APM shares are up 4.5% at $3.01 on the last check Wednesday.

Posted In: Biotech News Penny Stocks Health Care FDA General Phase 1 Trial Staphylococcus

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.